Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer by Kalantari, H Rezaei
Letter to the Editor
Predictive factors for severe toxicity of sunitinib in unselected
patients with advanced renal cell cancer
H Rezaei Kalantari*,1
1Department of Oncology, C.H. Peltzer - La Tourelle, Verviers, Belgium
British Journal of Cancer (2009) 101, 1222–1223. doi:10.1038/sj.bjc.6605303 www.bjcancer.com
Published online 15 September 2009
& 2009 Cancer Research UK
                
Sir,
In agreement with Van der Veldt et al (2008) and sunitinib
clinical trials (Motzer et al, 2007), we observe in our
clinical practice a significant proportion of patients who ultimately
need a sunitinib dose reduction as a consequence of intolerable
adverse events that cannot be effectively managed otherwise.
Hitherto often unreported, however, is the potential of a dose
re-escalation in patients who earlier required a sunitinib dose
reduction as a consequence of intolerable adverse events. Such a
dose re-escalation is clinically very relevant as a meta-analysis of
sunitinib studies previously showed that higher sunitinib plasma
levels were associated with a higher probability to achieve an
objective response, a longer time to progression and with an
improved overall survival (Houk et al, 2007). Two recent patient
cases from our own practice illustrate the relevance of a dose re-
escalation with sunitinib to achieve maximal patient benefit
and treatment outcome with this potent yet sometimes
challenging drug.
A 71-year-old patient with an imatinib-refractory gastrointest-
inal stromal tumor started sunitinib therapy at the recommended
50mg dose (4/2 schedule). After the first treatment cycle, fatigue
(grade: 2–3, grading according to the National Cancer Institute
Common Terminology Criteria for Adverse Events v3.0), lipo-
thymia (grade 2), anaemia (grade 1), leukopenia (grade 2) and
thrombocytopenia (grade 1) were observed. On the basis of these
adverse events, the second treatment cycle was tapered off to
alternating 37.5 and 25mg sunitinib daily doses (4/2 schedule). His
toxicities disappeared and his Eastern Cooperative Oncology
Group (ECOG) performance status (PS) improved from PS 2 to
PS 0 during the third cycle at this dosing regimen. Gradual dose
re-escalations to 37.5mg, alternating 50 and 37.5mg and 50mg
sunitinib daily doses (all 4/2 schedule) were subsequently
introduced in the fourth, fifth and sixth treatment cycles,
respectively, without any significant toxicity issues. At present,
the patient still remains on the 50mg dose, with good tolerance
and disease stabilisation.
A 47-year-old patient with renal cell carcinoma (RCC) was
started on sunitinib therapy at the 50mg once daily (4/2 schedule)
regimen. Fatigue, nausea, pruritus, articular erythroderma,
epistaxis (all grade 1) and hypertension and pruritus (grade 2)
developed, but these were effectively clinically managed and did
not require a modification of the sunitinib dose. During the second
treatment cycle, therapy appeared to be better tolerated, with
observations of mild fatigue, skin cracks and elevated transami-
nases (all grade 1) as remaining tolerance issues. After the third
treatment cycle, a partial response (RECIST criteria) was observed,
but tolerability deteriorated with increasing fatigue and skin
toxicity (although both are still considered grade 1), and the ECOG
PS deteriorated from PS 1 to PS 2. On the basis of these
observations, the fourth treatment cycle was down-titrated to
alternating 37.5 and 25mg sunitinib daily doses (4/2 schedule),
with improved patient tolerability: no toxicities were reported and
the PS improved from 2 to 0. The fifth treatment cycle was
continued at this dose, but the patient required hospitalisation for
abdominal pain and his PS deteriorated to 2. At that time, the
patient asked to cease sunitinib treatment, but we were able to
motivate the patient to continue therapy at 25mg sunitinib daily
doses (4/2 schedule). The sixth treatment cycle was associated with
a good tolerability and the PS improved to 1, but the CT scans
showed that the abdominal pain was associated with renewed
tumor growth. The sunitinib dose was therefore re-escalated to
50mg once daily (4/2 schedule) for the seventh treatment cycle,
during which the patient experienced a strong reduction in
abdominal pain (no further need for analgesics), a good
tolerability and PS 1. In an attempt to further optimise the
anti-tumor activity in this young patient, the sunitinib dose
was subsequently further up-titrated to 62.5mg once daily
(4/2 schedule) for the eighth treatment cycle, during which the
patient experienced no toxicity, an improvement in PS from 1 to 0
and was able to return back to work. This schedule is currently
being continued in the tenth treatment cycle with good tolerability,
PS 0 and further disease stabilisation.
Although dose reductions as a consequence of intolerable and
unmanageable adverse events are not infrequently required in
patients on sunitinib, our cases illustrate that it is equally
important to consider the potential of dose re-escalations in at
least some patients to maximise patient benefit and treatment
outcome. Kahl et al (2008) and Scho ¨ffski et al (2009) recently
reported similar observations of clinical benefit after sunitinib
dose re-escalation or escalation in progressing RCC patients.
Hence, in future studies of targeted agents, it will be useful to not
only report the frequency of dose reductions but also to report any
dose re-escalations in the patient population under study. Published online 15 September 2009
*Correspondence: Dr H Rezaei Kalantari;
E-mail: hassan_kalantari@hotmail.com
British Journal of Cancer (2009) 101, 1222–1223
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.comREFERENCES
Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR,
Wilding G, Motzer RJ (2007) Exposure-response of sunitinib in
metastatic renal cell carcinoma (mRCC): a population pharmaco-
kinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25: 5027
Kahl C, Hilgendorf I, Freund M, Casper J (2008) Continuous therapy
with sunitinib in patients with metastatic renal cell carcinoma. Onkologie
31: 485
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O,
Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM,
Figlin RA (2007) Sunitinib vs interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med 356: 115–124
Scho ¨ffski P, Bukowski R, Flodgren P, Ravaud A (2009) Tyrosine kinase
inhibition in renal cell carcinoma and gastrointestinal stromal tumours :
case reports. Ann Oncol 20(Suppl 1): i25–i30
van der Veldt AAM, Boven E, Helgason HH, van Wouwe M, Berkhof J,
de Gast G, Mallo H, Tillier CN, van den Eertwegh AJM, Haanen JBAG
(2008) Predictive factors for severe toxicity of sunitinib in unselected
patients with advanced renal cell cancer. Br J Cancer 99: 259–265
Letter to the Editor
1223
British Journal of Cancer (2009) 101(7), 1222–1223 & 2009 Cancer Research UK